PDCD1 and non-small cell lung carcinoma: In more detail, pembrolizumab (n = 17) [9,10,11,13,21,23,24,29,30,31,32,37,38,39,42] was cost-effective with respect to chemotherapy (SoC) when associated with a previous PD-1/PD-L1 assessment, in the first-line treatment of NSCLC [9,10,11,13,21,23,24,29,30,31,32,34,37,38,42].